SEC Tracker
Get the app

Zymeworks ZYME

Zymeworks raised 2026 revenue guidance to $337M-$351M

Zymeworks (ZYME) filed an 8-K with the SEC on Nov 9, 2026, 4:08 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Raised 2026 revenue guidance to $337 million to $351 million
  2. Received $250 million U.S. approval milestone for Ziihera
  3. Adjusted EBITDA guidance raised to $176 million to $190 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Zymeworks files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.